Workflow
Stride, Inc. Authorizes $500 Million Stock Repurchase Program
Globenewswire· 2025-11-03 22:00
RESTON, Va., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Stride, Inc. (NYSE: LRN) (“Stride,” the “Company,” “we,” or “our”), one of the nation’s most successful technology-based education companies, today announced the approval of a stock repurchase program that authorizes the repurchase of up to $500 million of shares of Stride’s common stock until October 31, 2026. “Stride’s Board of Directors and management team remain confident in the Company’s long-term outlook and believes in the investments we are making to up ...
SalMar - Invitation to presentation of the third quarter 2025 results
Globenewswire· 2025-11-03 22:00
SalMar presents results for the third quarter 2025 on Thursday 6 November 2025 at 08:00 CET. The presentation will be held at Grand Hotel in Oslo. Please note that the presentation will be held at Grand Hotel in Oslo, Karl Johans gate 31, and not at Hotel Continental as in previous quarterly presentations. CEO Frode Arntsen and CFO Ulrik Steinvik will be representing the company. The presentation will in addition be available on Norwegian webcast at 08:00 CET on www.salmar.no. There will be opportunity to s ...
Nokia and Rohde & Schwarz collaborate on AI-powered 6G receiver to cut costs, accelerate time to market
Globenewswire· 2025-11-03 22:00
Press ReleaseNokia and Rohde & Schwarz collaborate on AI-powered 6G receiver to cut costs, accelerate time to market AI-powered receiver technology using machine learning can greatly enhance future 6G coverage, creating cost savings and accelerating time to market.The AI technology identifies and compensates for distortion in wireless signals, leading to substantial improvements in 6G uplink coverage.Nokia and Rohde & Schwarz will demonstrate the technology at the Brooklyn 6G Summit from November 5-7. 3 Nov ...
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
Globenewswire· 2025-11-03 22:00
REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its completed Phase 2 study evaluating burixafor, a small molecule CXCR4 antagonist, will be featured in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida. The presentation will highlight additional ...
Gevo Makes First Delivery of Certified Carbon Credits to Biorecro, Unlocking Value from Carbon as a Co-Product
Globenewswire· 2025-11-03 22:00
Gevo expands its carbon business with the groundbreaking delivery, adding a new stream of repeatable revenue now including carbon removal credits (CORCs) in addition to ethanol, protein, vegetable oil, and tax credit salesENGLEWOOD, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) announced the production and delivery of certified carbon dioxide removal credits, known as CORCs under the high-integrity Puro.earth standard, to Biorecro North America, LLC, marking a major milestone in the com ...
MKS Inc. to Participate in Baird Global Industrial Conference
Globenewswire· 2025-11-03 22:00
ANDOVER, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MKS Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that Ram Mayampurath, Executive Vice President and Chief Financial Officer will be presenting at Baird Global Industrial Conference on Tuesday, November 11, 2025 at 3:55 p.m. EST. A live webcast of the session will be available in the Investor Relations section of the company's website at https://investor.mksinst.com/events-and-presentations and a r ...
Consolidated Water Wins $11.7 Million Contract to Build Wastewater Recycling Plant for San Francisco Bay Area Golf Club
Globenewswire· 2025-11-03 22:00
GEORGE TOWN, Cayman Islands, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, has been awarded a contract valued at $11.7 million to construct a wastewater recycling plant with 200,000 gallons-per-day capacity and 600,000 gallons of treated water storage for a San Francisco Bay Area golf club. The contract was secured by the company’s California-based subsidiary, PERC Wat ...
NewGen Announces Proposed Reverse Merger with SAXA, Inc. in a $5 Billion Mining Asset Acquisition Deal, Involving Gold, Silver, and Rare Earth
Globenewswire· 2025-11-03 22:00
NewGen will issue 500 million shares at US$10 to acquire the mining assets, substantially boosting shareholders’ equity and transforming the merged entity into a multi-billion-dollar conglomerateBANGKOK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health sol ...
New ROG XG Mobile eGPU Brings Desktop-Class Power to Laptops and Handhelds
Globenewswire· 2025-11-03 22:00
The new ROG external GPU delivers Thunderbolt™ 5, up to NVIDIA® GeForce RTX™ 5090 Laptop GPU, and improved cooling for peak portable performance, now in Canada KEY POINTS Performance Meets Versatility: XG Mobile features up to NVIDIA GeForce RTX 5090 Laptop GPU to power up your setup at a maximum 150W TGP.Thunderbolt™ 5 support: Future ready, while maintaining backward compatibility with Thunderbolt™ 4 and USB4 systems.Cooler and quieter: Redesigned vapor chamber with thicker channels and repositioned fan i ...
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
Globenewswire· 2025-11-03 22:00
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that data from its ongoing Phase 2 study of SLS009 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held Dec ...